Bob Ramsey of Kantar Health addresses the complexity of forecasting oncology products. The oncology market is facing new trends and therapies that present great opportunities for the future of pharma.

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

As our oncology focus month continues, Jim Furniss and Chris Teale discuss the market access environment for new oncology products in Europe, including sales comparisons with the US and their ...

Amneal and Shilpa are releasing Boruzu, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous administration. This new ready-to-use oncology product reduces ...

Predictive Oncology shares are trading higher on Tuesday after the company announced it developed predictive models to target various cancer types.

Kanvas Biosciences’ new research suggests that the company’s HiPR-Map Platform is capable of outperforming traditional ...

Despite vast investment in oncology R&D, the translation of research advances into medicines that substantially improve the treatment of many cancers remains frustratingly slow. What are the key ...

MIAMI, March 17, 2025--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined ...